Oral KRAS G12D Inhibitor GFH375 Tested in Phase 1 Solid Tumor Trial

Oral KRAS G12D inhibitor GFH375 enters phase 1 testing

Nature Medicine has published a phase 1 clinical trial report on GFH375, an oral drug designed to inhibit the KRAS G12D mutation. The article appeared online on 15 September 2026 and carries DOI 10.1038/s41591-026-04559-4. According to the publication metadata, the study evaluated GFH375 in patients with previously treated advanced solid tumors that harbor KRAS G12D mutations. The title describes GFH375 as an oral, dual on–off binding KRAS G12D inhibitor, a mechanistic detail that distinguishes it from some earlier KRAS-directed agents.

The record available for this article is brief. The excerpt begins by naming the journal, publication date, and DOI, then states that the phase 1 trial evaluated GFH375 in patients with KRASG12D-mu... The sentence is truncated in the metadata, but the title supplies the key framing: previously treated advanced solid tumors with KRAS G12D mutations. No efficacy percentages, safety tables, dose-escalation details, or response rates are included in the available metadata. That absence is important for readers: the publication's title and excerpt confirm the existence and scope of the trial, not its results.

What the trial title establishes

From the title and excerpt alone, several elements are clear. They are worth separating from speculation about outcomes.

• The study is a phase 1 trial, an early-stage human study.
• The investigational agent is GFH375.
• GFH375 is described as oral, meaning it is given by mouth rather than by infusion.
• GFH375 is described as a dual on–off binding KRAS G12D inhibitor.
• The target is the KRAS G12D mutation.
• The patient population had advanced solid tumors and had been previously treated.
• The report was published in Nature Medicine on 15 September 2026.

Why KRAS G12D attracts targeted-drug research

KRAS is one of the most frequently altered genes in human cancer. For decades it was considered difficult to drug because its protein product lacks obvious pockets for small molecules to bind. The arrival of KRAS G12C inhibitors changed that perception and energized efforts to target other KRAS variants. G12D is a distinct mutation: it replaces glycine with aspartic acid at position 12 of the KRAS protein. Tumors with this alteration are found across several cancer types, and because G12D differs structurally from G12C, drugs designed for one mutation are not automatically expected to work against the other.

The phase 1 title places GFH375 in this broader search for mutation-selective KRAS inhibitors. The phrase dual on–off binding suggests a design intended to interact with KRAS G12D in more than one conformational state. KRAS proteins cycle between active, GTP-bound forms and inactive, GDP-bound forms. A dual on–off binder may aim to block the target whether it is in an active or inactive state, though the metadata does not provide the trial's pharmacological data. The oral route is also notable because convenient administration can matter for chronic cancer therapy, provided bioavailability and tolerability are adequate.

What previously treated advanced solid tumors means

The trial enrolled patients whose cancers had already been treated. In oncology, previously treated usually means the disease has progressed after at least one prior line of therapy. Advanced solid tumors refers to cancers that are not confined to the original site and are generally not treated with curative intent. This is a typical population for a phase 1 study of a new targeted agent: patients who need additional options and whose tumors carry the molecular feature the drug is designed to inhibit.

The inclusion of KRAS G12D mutations makes this a biomarker-selected trial rather than an all-comers study. That design increases the likelihood that the drug is being tested in the patients most likely to benefit if the mechanism works. It also means the trial's eligibility depends on molecular testing of tumor tissue or blood to confirm the mutation. The title's wording strongly suggests that mutation status was a central eligibility criterion.

What phase 1 usually measures

A phase 1 trial is generally the first human testing step for an experimental therapy. Its primary goals often include assessing safety, tolerability, dose-limiting toxicities, and pharmacokinetics. Researchers also look for early signals of antitumor activity, but phase 1 studies are not designed to prove that a drug improves survival or beats standard treatment. Those questions require larger randomized trials.

Because this is a phase 1 report in a peer-reviewed journal, the publication likely describes the study design, patient characteristics, dosing, and observed outcomes. However, the available metadata does not include those numbers. Readers should therefore treat the article's appearance as a milestone in clinical development, not as evidence that GFH375 is already an approved or proven therapy. The title alone cannot establish response rate, duration of benefit, or the frequency of adverse events.

What the excerpt does not say

The excerpt ends mid-word after KRASG12D-mu, almost certainly a truncation of KRASG12D-mutated. It does not list the number of participants, the dose levels tested, the cancer types represented, the objective response rate, progression-free survival, overall survival, or safety findings. It also does not compare GFH375 with another treatment. Those details would be essential for judging the drug's clinical potential. Until they are available, any claim about how well GFH375 works in patients would be unsupported by the provided record.

It is also unclear from the metadata whether the trial is complete, ongoing, or reporting an interim analysis. The publication date of 15 September 2026 indicates when Nature Medicine posted the article online. The study itself may have been conducted over a longer period, and follow-up may continue after publication.

Why publication in Nature Medicine matters

Nature Medicine is a high-profile peer-reviewed journal that publishes clinical and translational research. Publication there suggests the phase 1 trial was considered sufficiently rigorous and relevant to warrant peer review and editorial attention. For a drug like GFH375, that visibility can influence how the oncology community views the KRAS G12D field. It may also shape subsequent trial design, investment, and interest in combination strategies.

Still, journal prestige does not substitute for efficacy data. A phase 1 publication can be important because it shows that a target is druggable, that a dosing strategy is feasible, or that a biological signal exists. It can also reveal toxicity that limits further development. The metadata here does not disclose which of those scenarios applies.

Questions that remain after this publication

• What were the dose-limiting toxicities and the maximum tolerated dose or recommended phase 2 dose?
• How many patients had a confirmed objective response, and in which tumor types?
• How long did responses last, and did they occur across different KRAS G12D-positive cancers?
• Did the dual on–off binding mechanism translate into measurable target engagement?
• Will GFH375 be tested in combination with other agents or in earlier lines of therapy?
• How do the results compare with other KRAS G12D-directed strategies in development?

Bottom line

GFH375 is an oral, dual on–off binding KRAS G12D inhibitor that has been evaluated in a phase 1 trial in patients with previously treated advanced solid tumors harboring KRAS G12D mutations. The study has been published in Nature Medicine with a DOI and an online date of 15 September 2026. Those facts establish the trial's scope and its place in precision oncology. They do not, by themselves, establish the drug's efficacy or safety profile. For now, the publication is a signal that this KRAS G12D program has reached the peer-reviewed clinical literature, while the key outcome data remain outside the available metadata.

This article is based on reporting by Nature Medicine. Read the original article.